🟢 Azitra is trading 5% up today after ATR-04 advances to the second cohort

Azitra is trading 5.45% up at $0.15 after its Phase 1/2 ATR-04 trial advanced to the second cohort following a safety review.

• The company announced the update on October 1, 2026.
• ATR-04 is being developed for skin rashes associated with EGFR inhibitors.
• No trading-volume information was available in the supplied price context or retrieved sources.